ESMO – European Society for Medical Oncology shared a post on LinkedIn:
“Abstract submission for ESMOTATAsia26 is now open!
The ESMO Targeted Anticancer Therapies Asia Congress 2026 brings together leading scientists, clinicians, and industry experts to explore the latest advances in precision medicine and targeted therapies
Why attend?
- Gain insights into cutting-edge research and clinical applications
- Discover novel strategies shaping the future of cancer care
- Network with global oncology leaders and innovators
- Participate in interactive sessions and discussions on emerging therapies
New this year: Trial in Progress abstracts accepted across all clinical phases.
Don’t miss this opportunity to be part of the conversation that defines next-generation hashtag#cancertreatment
Submit by 31 March 2026.”
More posts about ESMOTATAsia26.